Recent Updates
Recently added Catalysts
IMRX Positive Sentiment

Tyler Mead

Saturday, December 27, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Mr. Tyler Mead has a notable background in the Pharma and Life Sciences sectors, having started his career at PwC. He has provided audit services and guidance on compliance and financial reporting. Mr. Mead holds a B.S. in Accounting from Providence College and is a Certified Public Accountant in New Jersey.
Price reaction · baseline $6.73 (2025-12-26 close) · 41 other IMRX headline(s) in the window, move may be shared
day 0 close · peak
-1%

Market Sentiment Analysis

POSITIVE FACTORS

  • Mr. Mead has a strong background in Pharma/Life Sciences.
  • He is a Certified Public Accountant, indicating expertise.
  • His experience includes providing audit services to clients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor

Full Press Release Details

Mr. Mead began his career at PwC in the Pharma/Life Sciences Assurance practice. Throughout his tenure, he provided various audit services to clients, including guidance on internal controls compliance, financial reporting requirements, and various technical accounting topics. Mr. Mead received his B.S. in Accounting from Providence College, and is a Certified Public Accountant in New Jersey.

Frequently Asked Questions

What is Tyler Mead's professional background?

Tyler Mead has a background in Pharma/Life Sciences, starting at PwC.

Where did Tyler Mead receive his education?

He received his B.S. in Accounting from Providence College.

Is Tyler Mead a certified accountant?

Yes, he is a Certified Public Accountant in New Jersey.

What services did Tyler Mead provide at PwC?

He provided audit services and guidance on compliance and reporting.

ShareAdd on Google
Tags: IMRX Viatris Investor Conferences Healthcare Tyler Mead Pharma Life Sciences CPA PwC
Last updated: Dec 27, 2025

Biotech snapshot

Cash runway
$202M liquidity · $6M/mo burn
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 MonotherapyPhase 1
Advanced Solid Tumor →

Catalyst track record

+41%
best trade around IMRX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for IMRX.

See every catalyst's timing & PoA →